drugset / Trial / NCT05180994
Topical Infliximab in Eyes With Penetrating Keratoplasty
Phase 1/2
Recruiting
50 enrolled
University of Montreal Hospital Centre (CHUM)
Fonds de recherche en ophtalmologie de l'Université de Montréal · collabMaisonneuve-Rosemont Hospital · collabNiagara Health System · collabOttawa Hospital Research Institute · collabPrism Eye Institute · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2027-03-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 10 mg/ml | Topical |